RUSFERTIDE ACETATE | N220605 | TAKEDA PHARMACEUTICALS AMERICA INC
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 9822157Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Mar 17, 2034 | — | Yes | Yes | — | — |
| 10030061Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Mar 17, 2034 | — | Yes | Yes | — | — |
| 10442846Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Mar 17, 2034 | — | Yes | Yes | — | |
| 10501515Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Mar 17, 2034 | — | Yes | — | — | |
| 11807674Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Mar 17, 2034 | — | — | Yes | — | |
| 12269856Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Mar 17, 2034 | — | — | — | — |
| Code | Date | Status |
|---|---|---|
| NCENewly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 28, 2031 | Active |
Takeda Pharmaceuticals added new chemical entity exclusivity to MIMRYLO (rusfertide acetate), expiring Aug 2031.
New: MIMRYLO (RUSFERTIDE ACETATE) — exclusivity NCE exp 08/28/2031
Takeda added new chemical entity (NCE) exclusivity to Mimrylo (rusfertide acetate), expiring Aug 2031, providing five years of regulatory exclusivity from its NDA approval date.
New: MIMRYLO (RUSFERTIDE ACETATE) — exclusivity NCE exp 08/28/2031
Takeda Pharmaceuticals added new chemical entity (NCE) exclusivity to Mimrylo (rusfertide acetate), expiring Aug 2031.
New: MIMRYLO (RUSFERTIDE ACETATE) — exclusivity NCE exp 08/28/2031
Takeda Pharmaceuticals added new chemical entity (NCE) exclusivity to MIMRYLO (rusfertide acetate), expiring Aug 2031.
New: MIMRYLO (RUSFERTIDE ACETATE) — exclusivity NCE exp 08/28/2031
Takeda Pharmaceuticals added new chemical entity (NCE) exclusivity to MIMRYLO (rusfertide acetate), expiring Aug 2031.
New: MIMRYLO (RUSFERTIDE ACETATE) — exclusivity NCE exp 08/28/2031